Predicting & Preventing Adverse Maternal & Child Outcomes of Opioid Use

Status Recruiting

Clinical Trial Summary

This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.

Clinical Trial Description

Background: 7% of pregnant women in the U.S. use opioids and 21% of these women report misuse, making opioid use disorder (OUD) a major public health concern during pregnancy. The number of infants born with prenatal opioid exposure, neonatal opioid withdrawal syndrome (NOWS) and costly prolonged hospitalization has increased exponentially. The opioid epidemic is further worsened by the ongoing COVID-19 pandemic. Despite medication treatment for OUD with buprenorphine (BUP) or methadone (METH), these pregnant women continue to be at high risk for early relapse, polysubstance use, and depression. These infants are at risk for not only immediate NOWS and also poor long-term neurodevelopmental and behavioral outcomes. Genetic factors influence 30-60% of opioid adverse events (AEs). In pregnant women on medication management for OUD, and infants receiving opioids for NOWS treatment there is variability in dose required to prevent withdrawal symptoms and craving, likely related to physiological alterations, upregulation of metabolic and biological pathways, determined in part by opioid pharmacogenomics. Investigators have shown that in children and adults, opioid related poor clinical outcomes are related to opioid receptor genetic variations and resulting variations in their metabolism. Maternal depression and anxiety increase the risks for OUD, maternal relapse, NOWS and negatively impact pregnant women and their children. Thus, there is an urgent and unmet clinical need for a reliable tool to proactively predict maternal relapse, NOWS, and improve the safety of pregnant women with OUD and their children. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05942313
Study type	Observational
Source	University of Pittsburgh
Contact	Amy Monroe, MPH, MBA
Phone	412-623-6382
Email	monroeal@upmc.edu
Status	Recruiting
Phase
Start date	August 28, 2023
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05017974` - Research on Improving Sleep During Pregnancy	N/A
Completed	`NCT03284515` - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting	`NCT05969795` - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support	Phase 1
Recruiting	`NCT06051201` - Innovation for Small-scale Experiments: ReceptIVFity Test	N/A
Recruiting	`NCT04828382` - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation	`NCT04527926` - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy	N/A
Recruiting	`NCT04278651` - Early Antenatal Support for Iron Deficiency Anemia	Phase 4
Recruiting	`NCT04405700` - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting	`NCT06258902` - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed	`NCT05487196` - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia	Phase 2
Completed	`NCT03750968` - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects	Phase 2
Enrolling by invitation	`NCT06127277` - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care	N/A
Completed	`NCT05897697` - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting	`NCT05899101` - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed	`NCT05502510` - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed	`NCT04296396` - Opioid Prescription After Cesarean Trial	Phase 3
Not yet recruiting	`NCT06069856` - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial	Phase 3
Not yet recruiting	`NCT06069869` - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial	Phase 3
Not yet recruiting	`NCT06163651` - Evaluating a One-Year Version of the Parent-Child Assistance Program	N/A
Not yet recruiting	`NCT06079918` - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms